Wan-Ping Lee

Dr. Wan-Ping Lee

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Nature Genetics
Verified
Journal Article
Closed access
GRGoran Rakocevic
Goran Rakocevic
VSVladimir Semenyuk
Vladimir Semenyuk
WLWan-Ping Lee
Wan-Ping Lee
JSJames Spencer
James Spencer
JBJohn Browning
John Browning
DKDeniz Kural
Deniz Kural

9 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KFKurt Farrell
Kurt Farrell
JHJack Humphrey
Jack Humphrey
TCTimothy Chang
Timothy Chang
YZYi Zhao
Yi Zhao
YLYuk Yee Leung
Yuk Yee Leung
ANAdam Naj
Adam Naj
Progressive supranuclear palsy (PSP), a rare Parkinsonian disorder, is characterized by problems with movement, balance, and cognition. PSP differs from Alzheimer’s disease (AD) and other diseases, displaying abnormal microtubule-associated protein tau by both neuronal and glial cell pathologies. Genetic contributors may mediate these differences; however, the genetics of PSP remain underexplored. Here we conduct the largest genome-wide association study (GWAS) of PSP which includes 2779 cases (2595 neuropathologically-confirmed) and 5584 controls and identify six independent PSP susceptibility loci with genome-wide significant (P < 5 × 10−8) associations, including five known (MAPT, MOBP, STX6, RUNX2, SLCO1A2) and one novel locus (C4A). Integration with cell type-specific epigenomic annotations reveal an oligodendrocytic signature that might distinguish PSP from AD and Parkinson’s disease in subsequent studies. Candidate PSP risk gene prioritization using expression quantitative trait loci (eQTLs) identifies oligodendrocyte-specific effects on gene expression in half of the genome-wide significant loci, and an association with C4A expression in brain tissue, which may be driven by increased C4A copy number. Finally, histological studies demonstrate tau aggregates in oligodendrocytes that colocalize with C4 (complement) deposition. Integrating GWAS with functional studies, epigenomic and eQTL analyses, we identify potential causal roles for variation in MOBP, STX6, RUNX2, SLCO1A2, and C4A in PSP pathogenesis.

16 August 2024 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
HWHui Wang
Hui Wang
TCTimothy S. Chang
Timothy S. Chang
BDBeth A. Dombroski
Beth A. Dombroski
PCPo-Liang Cheng
Po-Liang Cheng
VPVishakha Patil
Vishakha Patil
WLWan-Ping Lee
Wan-Ping Lee
Background: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease characterized by the accumulation of aggregated tau proteins in astrocytes, neurons, and oligodendrocytes. Previous genome-wide association studies for PSP were based on genotype array, therefore, were inadequate for the analysis of rare variants as well as larger mutations, such as small insertions/deletions (indels) and structural variants (SVs). Method: In this study, we performed whole genome sequencing (WGS) and conducted association analysis for single nucleotide variants (SNVs), indels, and SVs, in a cohort of 1,718 cases and 2,944 controls of European ancestry. Of the 1,718 PSP individuals, 1,441 were autopsy-confirmed and 277 were clinically diagnosed. Results: Our analysis of common SNVs and indels confirmed known genetic loci at MAPT, MOBP, STX6, SLCO1A2, DUSP10, and SP1, and further uncovered novel signals in APOE, FCHO1/MAP1S, KIF13A, TRIM24, TNXB, and ELOVL1. Notably, in contrast to Alzheimer’s disease (AD), we observed the APOE ε2 allele to be the risk allele in PSP. Analysis of rare SNVs and indels identified significant association in ZNF592 and further gene network analysis identified a module of neuronal genes dysregulated in PSP. Moreover, seven common SVs associated with PSP were observed in the H1/H2 haplotype region (17q21.31) and other loci, including IGH, PCMT1, CYP2A13, and SMCP. In the H1/H2 haplotype region, there is a burden of rare deletions and duplications (P = 6.73 × 10–3) in PSP. Conclusions: Through WGS, we significantly enhanced our understanding of the genetic basis of PSP, providing new targets for exploring disease mechanisms and therapeutic interventions.

13 December 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
YJYukyung Jun
Yukyung Jun
YSYun-Suhk Suh
Yun-Suhk Suh
SPSungHee Park
SungHee Park
JLJieun Lee
Jieun Lee
JKJong-Il Kim
Jong-Il Kim
CLCharles Lee
Charles Lee
Alternatively spliced RNA isoforms are a hallmark of tumors, but their nature, prevalence, and clinical implications in gastric cancer have not been comprehensively characterized. We systematically profiled the splicing landscape of 83 gastric tumors and matched normal mucosa, identifying and experimentally validating eight splicing events that can classify all gastric cancers into three subtypes: epithelial-splicing (EpiS), mesenchymal-splicing (MesS), and hybrid-splicing. These subtypes were associated with distinct molecular signatures and epithelial–mesenchymal transition markers. Subtype-specific splicing events were enriched in motifs for splicing factors RBM24 and ESRP1, which were upregulated in MesS and EpiS tumors, respectively. A simple classifier based only on RNA levels of RBM24 and ESRP1, which can be readily implemented in the clinic, was sufficient to distinguish gastric cancer subtypes and predict patient survival in multiple independent patient cohorts. Overall, this study provides insights into alternative splicing in gastric cancer and the potential clinical utility of splicing-based patient classification. Significance: This study presents a comprehensive analysis of alternative splicing in the context of patient classification, molecular mechanisms, and prognosis in gastric cancer.

8 February 2023 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
HWHui Wang
Hui Wang
LWLi-San Wang
Li-San Wang
GSGerard Schellenberg
Gerard Schellenberg
WLWan-Ping Lee
Wan-Ping Lee
Dozens of single nucleotide polymorphisms (SNPs) related to Alzheimer’s disease (AD) have been discovered by large scale genome-wide association studies (GWASs). However, only a small portion of the genetic component of AD can be explained by SNPs observed from GWAS. Structural variation (SV) can be a major contributor to the missing heritability of AD; while SV in AD remains largely unexplored as the accurate detection of SVs from the widely used array-based and short-read technology are still far from perfect. Here, we briefly summarized the strengths and weaknesses of available SV detection methods. We reviewed the current landscape of SV analysis in AD and SVs that have been found associated with AD. Particularly, the importance of currently less explored SVs, including insertions, inversions, short tandem repeats, and transposable elements in neurodegenerative diseases were highlighted.

17 June 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
HWHui Wang
Hui Wang
BDBeth A. Dombroski
Beth A. Dombroski
PCPo‐Liang Cheng
Po‐Liang Cheng
ATAlbert Tucci
Albert Tucci
YSYa‐Qin Si
Ya‐Qin Si
WLWan-Ping Lee
Wan-Ping Lee
INTRODUCTION: The role of structural variations (SVs) in Alzheimer's disease (AD) remains understudied.METHODS: We analyzed whole‐genome sequencing data from the Alzheimer's Disease Sequencing Project (N = 16,543) and identified 400,234 (168,223 high‐quality) SVs. Laboratory validation yielded a sensitivity of 82% (85% for high‐quality).RESULTS: We found a burden of singletons (odds ratio [OR] = 1.07, p = 0.0017) and homozygous deletions (OR = 1.14, p < 0.0001) in cases. On AD genes, we observed the ultra‐rare SVs associated with the disease, including protein‐altering SVs in ABCA7, APP, PLCG2, and SORL1. Twenty‐one SVs are in linkage disequilibrium (LD) with known AD‐risk variants, exemplified by a 5k deletion in LD (R2 = 0.99) with rs143080277 in NCK2. We identified a rare deletion near RNA5SP293 associated with AD (OR = 1.99, p = 1.3 × 10−5), which was replicated using an independent dataset.DISCUSSION: This study highlights the pivotal role of SVs in AD genetics.Highlights: Observed a significant burden of singletons and homozygous deletions in Alzheimer's disease (AD) patients. Identified rare protein‐altering structural variations (SVs) in ABCA7, APP, PLCG2, and SORL1. Established linkages between SVs and AD risk‐associated single nucleotide variants (SNVs). Discovered a novel deletion near RNA5SP293 linked to AD, replicated independently. Uncovered over‐representation of SVs in neuronal function pathways.